Literature DB >> 17851084

Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides.

Anna M Kauppi1, C David Andersson, Henrik A Norberg, Charlotta Sundin, Anna Linusson, Mikael Elofsson.   

Abstract

Compound 1, 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-(3,4-dichloro-phenyl)-benzamide, was identified as a putative type III secretion inhibitor in Yersinia, and the compound thus has a potential to be used to prevent or treat bacterial infections. A set of seven analogues was synthesized and evaluated in a type III secretion dependent reporter-gene assay with viable bacterial to give basic SAR. A second set of 19 compounds was obtained by statistical molecular design in the building block and product space and by subsequent synthesis. Evaluation in the reporter-gene assay showed that the compounds ranged from non-active to compounds more potent than 1. Based on the data multivariate QSAR models were established and the final Hi-PLS model showed good correlation between experimentally determined % inhibition and the calculated % inhibition of the reporter-gene signal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851084     DOI: 10.1016/j.bmc.2007.07.047

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

Review 1.  Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.

Authors:  Miles C Duncan; Roger G Linington; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

2.  The bacterial type III secretion system as a target for developing new antibiotics.

Authors:  Andrew C McShan; Roberto N De Guzman
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

3.  Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae.

Authors:  Hencelyn Chu; Anatoly Slepenkin; Mikael Elofsson; Pia Keyser; Luis M de la Maza; Ellena M Peterson
Journal:  Int J Antimicrob Agents       Date:  2010-06-01       Impact factor: 5.283

4.  Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model.

Authors:  Lynne K Garrity-Ryan; Oak K Kim; Joan-Miquel Balada-Llasat; Victoria J Bartlett; Atul K Verma; Michael L Fisher; Cynthia Castillo; Warangkhana Songsungthong; S Ken Tanaka; Stuart B Levy; Joan Mecsas; Michael N Alekshun
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

5.  Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.

Authors:  Jianfang Li; Chao Lv; Weiyang Sun; Zhenyu Li; Xiaowei Han; Yaoyao Li; Yuemao Shen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

6.  Substituted 2-imino-5-arylidenethiazolidin-4-one inhibitors of bacterial type III secretion.

Authors:  Toni Kline; Heather B Felise; Kathleen C Barry; Stona R Jackson; Hai V Nguyen; Samuel I Miller
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

7.  Targeting type III secretion in Yersinia pestis.

Authors:  Ning J Pan; Michael J Brady; John M Leong; Jon D Goguen
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

8.  Small molecules aimed at type III secretion systems to inhibit bacterial virulence.

Authors:  Lun K Tsou; Paul D Dossa; Howard C Hang
Journal:  Medchemcomm       Date:  2013-01-01       Impact factor: 3.597

9.  Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system.

Authors:  Toni Kline; Kathleen C Barry; Stona R Jackson; Heather B Felise; Hai V Nguyen; Samuel I Miller
Journal:  Bioorg Med Chem Lett       Date:  2009-01-20       Impact factor: 2.823

10.  Development of Chlamydial Type III Secretion System Inhibitors for Suppression of Acute and Chronic Forms of Chlamydial Infection.

Authors:  N A Zigangirova; E S Zayakin; L N Kapotina; E A Kost; L V Didenko; D Y Davydova; J P Rumyanceva; A L Gintsburg
Journal:  Acta Naturae       Date:  2012-04       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.